BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24191050)

  • 1. Rescue of a primary myelofibrosis model by retinoid-antagonist therapy.
    Hong SH; Dvorak-Ewell M; Stevens HY; Barish GD; Castro GL; Nofsinger R; Frangos JA; Shoback D; Evans RM
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18820-5. PubMed ID: 24191050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.
    Yan XQ; Lacey D; Hill D; Chen Y; Fletcher F; Hawley RG; McNiece IK
    Blood; 1996 Jul; 88(2):402-9. PubMed ID: 8695786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
    Vannucchi AM; Bianchi L; Paoletti F; Pancrazzi A; Torre E; Nishikawa M; Zingariello M; Di Baldassarre A; Rana RA; Lorenzini R; Alfani E; Migliaccio G; Migliaccio AR
    Blood; 2005 May; 105(9):3493-501. PubMed ID: 15665119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.
    Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; Raslova H; Villeval JL; Vainchenker W; Giraudier S
    J Immunol; 2006 Jun; 176(11):6425-33. PubMed ID: 16709799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis.
    Akiyama T; Matsunaga T; Terui T; Miyanishi K; Tanaka I; Sato T; Kuroda H; Takimoto R; Takayama T; Kato J; Yamauchi N; Kogawa K; Sakamaki S; Hirayama Y; Kohda K; Niitsu Y
    Leukemia; 2005 Sep; 19(9):1558-66. PubMed ID: 16034467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
    Chou JM; Li CY; Tefferi A
    Leuk Res; 2003 Jun; 27(6):499-504. PubMed ID: 12648509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.
    Ghanima W; Geyer JT; Lee CS; Boiocchi L; Imahiyerobo AA; Orazi A; Bussel JB
    Haematologica; 2014 May; 99(5):937-44. PubMed ID: 24463212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis.
    Kakumitsu H; Kamezaki K; Shimoda K; Karube K; Haro T; Numata A; Shide K; Matsuda T; Oshima K; Harada M
    Leuk Res; 2005 Jul; 29(7):761-9. PubMed ID: 15927672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.
    Evrard S; Bluteau O; Tulliez M; Rameau P; Gonin P; Zetterberg E; Palmblad J; Bonnefoy A; Villeval JL; Vainchenker W; Giraudier S; Wagner-Ballon O
    Blood; 2011 Jan; 117(1):246-9. PubMed ID: 20944070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin inhibits in vitro osteoclastogenesis from murine bone marrow cells.
    Wakikawa T; Shioi A; Hino M; Inaba M; Nishizawa Y; Tatsumi N; Morii H; Otani S
    Endocrinology; 1997 Oct; 138(10):4160-6. PubMed ID: 9322925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ALK5 inhibition in myelofibrosis.
    Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
    JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis.
    Ozaki S; Kosaka M; Ozaki K; Wakatsuki S; Hashimoto T; Miyazaki H
    Br J Haematol; 1997 May; 97(2):449-52. PubMed ID: 9163612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow.
    Wang JC; Hashmi G
    Leuk Res; 2003 Jan; 27(1):13-7. PubMed ID: 12479847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis.
    Martyré MC; Romquin N; Le Bousse-Kerdiles MC; Chevillard S; Benyahia B; Dupriez B; Demory JL; Bauters F
    Br J Haematol; 1994 Sep; 88(1):9-16. PubMed ID: 7803262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
    Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
    Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis.
    Nofsinger RR; Li P; Hong SH; Jonker JW; Barish GD; Ying H; Cheng SY; Leblanc M; Xu W; Pei L; Kang YJ; Nelson M; Downes M; Yu RT; Olefsky JM; Lee CH; Evans RM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):20021-6. PubMed ID: 19066220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.
    Bock O; Höftmann J; Theophile K; Hussein K; Wiese B; Schlué J; Kreipe H
    Am J Pathol; 2008 Apr; 172(4):951-60. PubMed ID: 18349123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.